| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael Gejl, Lærke Egefjord, Susanne Lerche, Kim Vang, Bo Martin Bibby, Jens Juul Holst, Annette Mengel, Niels Møller, Jørgen Rungby, Birgitte Brock, Albert Gjedd. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 32. issue 12. 2013-02-01. PMID:22929437. |
reports indicate that glucagon-like peptide-1 (glp-1) may be neuroprotective in models of ad and stroke: although the mechanism is unclear, glucose homeostasis appears to be important. |
2013-02-01 |
2023-08-12 |
Not clear |
| Joanna Hlebowicz, Sandra Lindstedt, Ola Björgell, Magnus Dencke. The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure. Cardiovascular ultrasound. vol 9. 2012-05-15. PMID:22206473. |
the aim of this study was to evaluate the effect of endogenously released glucose, insulin, glucagon-like peptide 1 (glp-1), ghrelin on co, hr, stroke volume (sv), and blood pressure. |
2012-05-15 |
2023-08-12 |
Not clear |
| Steven P Moberly, Zachary C Berwick, Meredith Kohr, Mark Svendsen, Kieren J Mather, Johnathan D Tun. Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Experimental biology and medicine (Maywood, N.J.). vol 237. issue 3. 2012-05-07. PMID:22345302. |
at normal perfusion pressure (100 mmhg), intracoronary glp-1 (7-36) (targeting plasma concentration 10 pmol/l to 1 nmol/l) did not affect blood pressure, coronary blood flow or myocardial oxygen consumption (mvo(2)); however, there were modest reductions in cardiac output and stroke volume. |
2012-05-07 |
2023-08-12 |
Not clear |
| Jens Juul Holst, Remy Burcelin, Esther Nathanso. Neuroprotective properties of GLP-1: theoretical and practical applications. Current medical research and opinion. vol 27. issue 3. 2011-06-14. PMID:21222567. |
this article summarizes the evidence for neuronal activity of glp-1 and examines the limited data that currently exist on the therapeutic potential of glp-1 in specific neurological and neurodegenerative conditions, namely alzheimer's disease, parkinson's disease, huntingdon's disease, stroke and peripheral sensory neuropathy. |
2011-06-14 |
2023-08-12 |
Not clear |
| Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti, Arnold Brossi, Debomoy K Lahiri, Mark P Mattson, Barry J Hoffer, Yun Wang, Nigel H Grei. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America. vol 106. issue 4. 2009-02-13. PMID:19164583. |
glp-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism. |
2009-02-13 |
2023-08-12 |
mouse |